FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030197758> ?p ?o ?g. }

• W2030197758 endingPage "492" @default.
• W2030197758 startingPage "492" @default.
• W2030197758 abstract "A large number of G-protein-coupled receptors (GPCRs) show varying degrees of basal or constitutive activity. This constitutive activity is usually minimal in natural receptors but is markedly observed in wild type and mutated (naturally or induced) receptors. According to conventional two-state drug receptor interaction model, binding of a ligand may initiate activity (agonist with varying degrees of positive intrinsic activity) or prevent the effect of an agonist (antagonist with zero intrinsic activity). Inverse agonists bind with the constitutively active receptors, stabilize them, and thus reduce the activity (negative intrinsic activity). Receptors of many classes (α-and β-adrenergic, histaminergic, GABAergic, serotoninergic, opiate, and angiotensin receptors) have shown basal activity in suitable in vitro models. Several drugs that have been conventionally classified as antagonists (β-blockers, antihistaminics) have shown inverse agonist effects on corresponding constitutively active receptors. Nearly all H ₁ and H ₂ antihistaminics (antagonists) have been shown to be inverse agonists. Among the β-blockers, carvedilol and bucindolol demonstrate low level of inverse agonism as compared to propranolol and nadolol. Several antipsychotic drugs (D ₂ receptors antagonist), antihypertensive (AT ₁ receptor antagonists), antiserotoninergic drugs and opioid antagonists have significant inverse agonistic activity that contributes partly or wholly to their therapeutic value. Inverse agonism may also help explain the underlying mechanism of beneficial effects of carvedilol in congestive failure, naloxone-induced withdrawal syndrome in opioid dependence, clozapine in psychosis, and candesartan in cardiac hypertrophy. Understanding inverse agonisms has paved a way for newer drug development. It is now possible to develop agents, which have only desired therapeutic value and are devoid of unwanted adverse effect. Pimavanserin (ACP-103), a highly selective 5-HT _2A inverse agonist, attenuates psychosis in patients with Parkinson's disease with psychosis and is devoid of extrapyramidal side effects. This dissociation is also evident from the development of anxioselective benzodiazepines devoid of habit-forming potential. Hemopressin is a peptide ligand that acts as an antagonist as well as inverse agonist. This agent acts as an antinociceptive agent in different in vivo models of pain. Treatment of obesity by drugs having inverse agonist activity at CB _1/2 receptors is also underway. An exciting development is evaluation of β-blockers in chronic bronchial asthma-a condition akin to congestive heart failure where β-blockade has become the standard mode of therapy. Synthesis and evaluation of selective agents is underway. Therefore, inverse agonism is an important aspect of drug-receptor interaction and has immense untapped therapeutic potential." @default.
• W2030197758 created "2016-06-24" @default.
• W2030197758 creator A5035943606 @default.
• W2030197758 creator A5083064128 @default.
• W2030197758 date "2011-01-01" @default.
• W2030197758 modified "2023-10-02" @default.
• W2030197758 title "Inverse agonism and its therapeutic significance" @default.
• W2030197758 cites W117176610 @default.
• W2030197758 cites W1557560429 @default.
• W2030197758 cites W1579548382 @default.
• W2030197758 cites W1664200544 @default.
• W2030197758 cites W1742985083 @default.
• W2030197758 cites W1886812212 @default.
• W2030197758 cites W1963567484 @default.
• W2030197758 cites W1964191104 @default.
• W2030197758 cites W1967630951 @default.
• W2030197758 cites W1968107218 @default.
• W2030197758 cites W1970021822 @default.
• W2030197758 cites W1975454274 @default.
• W2030197758 cites W1975730235 @default.
• W2030197758 cites W1981731045 @default.
• W2030197758 cites W1984308291 @default.
• W2030197758 cites W1989046747 @default.
• W2030197758 cites W1990401009 @default.
• W2030197758 cites W1992935336 @default.
• W2030197758 cites W1994103758 @default.
• W2030197758 cites W2000587715 @default.
• W2030197758 cites W2006796554 @default.
• W2030197758 cites W2008985170 @default.
• W2030197758 cites W2017659544 @default.
• W2030197758 cites W2025176041 @default.
• W2030197758 cites W2026800992 @default.
• W2030197758 cites W2036970863 @default.
• W2030197758 cites W2045208022 @default.
• W2030197758 cites W2050828219 @default.
• W2030197758 cites W2053404013 @default.
• W2030197758 cites W2054935554 @default.
• W2030197758 cites W2056770521 @default.
• W2030197758 cites W2062413775 @default.
• W2030197758 cites W2065424661 @default.
• W2030197758 cites W2067693762 @default.
• W2030197758 cites W2068477597 @default.
• W2030197758 cites W2069478559 @default.
• W2030197758 cites W2070159491 @default.
• W2030197758 cites W2071841509 @default.
• W2030197758 cites W2080186455 @default.
• W2030197758 cites W2084723116 @default.
• W2030197758 cites W2087135060 @default.
• W2030197758 cites W2092104992 @default.
• W2030197758 cites W2102018049 @default.
• W2030197758 cites W2107897296 @default.
• W2030197758 cites W2110133277 @default.
• W2030197758 cites W2110470644 @default.
• W2030197758 cites W2110612597 @default.
• W2030197758 cites W2111391885 @default.
• W2030197758 cites W2118300866 @default.
• W2030197758 cites W2121192347 @default.
• W2030197758 cites W2128827219 @default.
• W2030197758 cites W2129788952 @default.
• W2030197758 cites W2138004092 @default.
• W2030197758 cites W2138191190 @default.
• W2030197758 cites W2143957256 @default.
• W2030197758 cites W2144335734 @default.
• W2030197758 cites W2147549437 @default.
• W2030197758 cites W2149649063 @default.
• W2030197758 cites W2154500741 @default.
• W2030197758 cites W2167071150 @default.
• W2030197758 cites W2171321165 @default.
• W2030197758 cites W2208580072 @default.
• W2030197758 cites W2259399904 @default.
• W2030197758 cites W2316111189 @default.
• W2030197758 cites W2998034180 @default.
• W2030197758 cites W62631408 @default.
• W2030197758 doi "https://doi.org/10.4103/0253-7613.84947" @default.
• W2030197758 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3195115" @default.
• W2030197758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22021988" @default.
• W2030197758 hasPublicationYear "2011" @default.
• W2030197758 type Work @default.
• W2030197758 sameAs 2030197758 @default.
• W2030197758 citedByCount "53" @default.
• W2030197758 countsByYear W20301977582013 @default.
• W2030197758 countsByYear W20301977582014 @default.
• W2030197758 countsByYear W20301977582015 @default.
• W2030197758 countsByYear W20301977582016 @default.
• W2030197758 countsByYear W20301977582017 @default.
• W2030197758 countsByYear W20301977582018 @default.
• W2030197758 countsByYear W20301977582019 @default.
• W2030197758 countsByYear W20301977582020 @default.
• W2030197758 countsByYear W20301977582021 @default.
• W2030197758 countsByYear W20301977582022 @default.
• W2030197758 countsByYear W20301977582023 @default.
• W2030197758 crossrefType "journal-article" @default.
• W2030197758 hasAuthorship W2030197758A5035943606 @default.
• W2030197758 hasAuthorship W2030197758A5083064128 @default.
• W2030197758 hasBestOaLocation W20301977582 @default.
• W2030197758 hasConcept C126322002 @default.
• W2030197758 hasConcept C135285700 @default.
• W2030197758 hasConcept C170493617 @default.

• next